Edition:
United States

Merck & Co Inc (MRK)

MRK on New York Consolidated

64.04USD
22 May 2017
Change (% chg)

$0.26 (+0.41%)
Prev Close
$63.78
Open
$63.70
Day's High
$64.44
Day's Low
$63.57
Volume
6,226,549
Avg. Vol
10,005,928
52-wk High
$66.80
52-wk Low
$54.78

Select another date:

BRIEF-Merck announces presentation of phase 2 results for MK-7264

* Merck announces presentation of phase 2 results for MK-7264, an investigational, p2x3 receptor antagonist, being evaluated for the treatment of chronic cough

BRIEF-Ablynx to receive 15 million euros milestone payment

* NOVEL NANOBODY TO START CLINICAL DEVELOPMENT IN OSTEOARTHRITIS - ABLYNX TO RECEIVE €15 MILLION MILESTONE PAYMENT

BRIEF-Merck receives CHMP positive opinion recommending approval of isentress

* Merck receives chmp positive opinion recommending approval of isentress® (raltegravir) 600 mg in the european union

Merck, Incyte immunotherapy combination effective in lung cancer study

A combination of the Merck & Co immunotherapy Keytruda and a different type of drug that also helps the immune system fight cancer from Incyte Corp led to a high rate of durable responses in a small, ongoing study of patients with advanced lung cancer, according to data released on Wednesday.

Merck says test shows Keytruda improves survival for bladder cancer patients

Pivotal trial results for Merck & Co Inc's immunotherapy drug Keytruda show that it lengthened survival by three months, or nearly 40 percent, for patients with advanced bladder cancer who had stopped responding to chemotherapy.

UPDATE 1-Merck says test shows Keytruda improves survival for bladder cancer patients

May 17 Pivotal trial results for Merck & Co Inc's immunotherapy drug Keytruda show that it lengthened survival by three months, or nearly 40 percent, for patients with advanced bladder cancer who had stopped responding to chemotherapy.

Merck, Incyte immunotherapy combination effective in lung cancer study

A combination of the Merck & Co immunotherapy Keytruda and a different type of drug that also helps the immune system fight cancer from Incyte Corp led to a high rate of durable responses in a small, ongoing study of patients with advanced lung cancer, according to data released on Wednesday.

UPDATE 1-Merck, Incyte immunotherapy combination effective in lung cancer study

May 17 A combination of the Merck & Co immunotherapy Keytruda and a different type of drug that also helps the immune system fight cancer from Incyte Corp led to a high rate of durable responses in a small, ongoing study of patients with advanced lung cancer, according to data released on Wednesday.

Merck says test shows Keytruda improves survival for bladder cancer patients

May 17 Pivotal trial results for Merck & Co Inc's immunotherapy drug Keytruda show that it lengthened survival by three months, or nearly 40 percent, for patients with advanced bladder cancer who had stopped responding to chemotherapy.

Merck, Incyte immunotherapy combination effective in lung cancer study

May 17 A combination of the Merck & Co immunotherapy Keytruda and a different type of drug that also helps the immune system fight cancer from Incyte Corp led to a high rate of durable responses in a small, ongoing study of patients with advanced lung cancer, according to data released on Wednesday.

Select another date:

More From Around the Web